Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meningococcal Conjugate Vaccine Studies May Use Immunologic Correlates

Executive Summary

Immunologic correlates may be used to predict protective efficacy of meningococcal conjugate vaccines, FDA's Vaccines and Related Biological Products Advisory Committee agreed at a Sept. 15 meeting in Bethesda, Md.

You may also be interested in...



Pediatric Meningococcal Vaccine's Approval Pathway May Work For Other Disease Areas

FDA suggests serum bactericidal antibody measurements to predict protection from meningococcal diseases in children under age 2.

Abbott Ends Certiva Agreement In U.S.; NAVA Focuses on NeisVac-C for U.K.

Abbott has terminated its agreement with North American Vaccine to market its combination diphtheria, tetanus and acellular pertussis vaccine Certiva to private physicians in the U.S.

Abbott Ends Certiva Agreement In U.S.; NAVA Focuses on NeisVac-C for U.K.

Abbott has terminated its agreement with North American Vaccine to market its combination diphtheria, tetanus and acellular pertussis vaccine Certiva to private physicians in the U.S.

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel